This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
blood donors | 1185 |
hbv dna | 858 |
blood transfusion | 856 |
chronic hepatitis | 675 |
whole blood | 666 |
hbv infection | 640 |
blood donation | 603 |
red blood | 598 |
blood components | 583 |
study design | 543 |
blood products | 526 |
blood group | 498 |
summary conclusions | 494 |
case studies | 488 |
red cell | 484 |
background case | 481 |
virus infection | 467 |
liver failure | 454 |
blood bank | 433 |
breast milk | 404 |
blood cells | 394 |
design method | 390 |
results finding | 375 |
transfusion medicine | 354 |
blood donor | 323 |
red cells | 310 |
blood cell | 304 |
hepatocellular carcinoma | 277 |
liver disease | 261 |
platelet concentrates | 253 |
nucleic acid | 252 |
iu ml | 246 |
viral load | 246 |
transfusion reactions | 245 |
immune response | 243 |
control group | 240 |
significantly higher | 237 |
copies ml | 229 |
significant difference | 228 |
united states | 226 |
adverse events | 226 |
blood banks | 218 |
transfusion service | 214 |
platelet count | 210 |
blood supply | 209 |
blood donations | 206 |
immune responses | 205 |
immunodeficiency virus | 202 |
human immunodeficiency | 201 |
pregnant women | 198 |
blood units | 196 |
flow cytometry | 195 |
risk factors | 194 |
influenza virus | 194 |
blood samples | 192 |
blood collection | 192 |
chronic hbv | 190 |
hcv rna | 186 |
blood center | 184 |
two groups | 183 |
infectious diseases | 181 |
hcv infection | 181 |
ng ml | 180 |
stem cell | 174 |
viral replication | 172 |
antiviral therapy | 172 |
virus replication | 172 |
blood safety | 169 |
time pcr | 166 |
liver transplantation | 166 |
hbv replication | 166 |
quality control | 164 |
surface antigen | 164 |
blood product | 164 |
gene expression | 163 |
performed using | 163 |
bone marrow | 160 |
statistically significant | 157 |
chronic liver | 154 |
mg dl | 153 |
viral infections | 152 |
virus type | 152 |
peripheral blood | 152 |
renal failure | 150 |
heat shock | 150 |
clinical trials | 149 |
liver cirrhosis | 147 |
results findings | 144 |
blood services | 141 |
west nile | 140 |
viral dna | 140 |
design methods | 138 |
bacterial contamination | 137 |
transfusion services | 137 |
hepg cells | 136 |
liver function | 135 |
infected patients | 132 |
blood component | 132 |
clinically significant | 132 |
viral infection | 130 |
rbc units | 128 |
side effects | 126 |
amino acid | 124 |
chb patients | 124 |
cell line | 123 |
first time | 123 |
clinical practice | 122 |
acute respiratory | 121 |
national blood | 121 |
nile virus | 121 |
donor selection | 121 |
viral hepatitis | 120 |
infected cells | 120 |
antibody screening | 119 |
blood centers | 119 |
dengue virus | 119 |
blood service | 118 |
hiv infection | 118 |
cell lines | 117 |
autologous blood | 115 |
patients receiving | 115 |
severe hepatitis | 114 |
antiglobulin test | 114 |
significant differences | 114 |
viral rna | 113 |
immune system | 112 |
shock protein | 112 |
liver injury | 112 |
dna levels | 111 |
severe acute | 111 |
mg kg | 111 |
red cross | 111 |
room temperature | 110 |
positive samples | 110 |
respiratory syndrome | 109 |
patients undergoing | 108 |
antiviral activity | 108 |
platelet transfusion | 108 |
frozen plasma | 108 |
present study | 107 |
cell responses | 107 |
positive results | 107 |
health care | 106 |
years old | 106 |
adverse reactions | 105 |
mean age | 105 |
blood loss | 105 |
liver biopsy | 105 |
blood groups | 103 |
public health | 102 |
university hospital | 102 |
important role | 102 |
rbc transfusion | 102 |
cell culture | 100 |
increased risk | 100 |
may also | 100 |
dna level | 98 |
antiviral drugs | 98 |
combination therapy | 98 |
intensive care | 97 |
fresh frozen | 97 |
high risk | 96 |
positive patients | 96 |
core protein | 96 |
patients treated | 95 |
type i | 95 |
serum hbv | 94 |
pg ml | 94 |
risk factor | 93 |
recent years | 92 |
liver diseases | 92 |
per year | 92 |
factor viii | 91 |
western blot | 91 |
viral proteins | 90 |
transfusion practice | 90 |
medical center | 89 |
blood volume | 89 |
patients received | 89 |
antiviral treatment | 89 |
class i | 89 |
stem cells | 88 |
specific antibodies | 88 |
cardiac surgery | 87 |
cd cells | 87 |
drug resistance | 87 |
transfusion reaction | 86 |
cord blood | 86 |
cell surface | 86 |
total number | 86 |
antibody screen | 85 |
sickle cell | 85 |
general population | 85 |
blood transfusions | 84 |
herpes simplex | 84 |
transfusion therapy | 84 |
pathogen inactivation | 83 |
plasma samples | 83 |
blood pressure | 83 |
female donors | 83 |
chain reaction | 83 |
amino acids | 83 |
acute liver | 83 |
safe blood | 83 |
time donors | 82 |
one patient | 81 |
monoclonal antibody | 80 |
group system | 80 |
polymerase chain | 79 |
hbv genome | 79 |
massive transfusion | 79 |
significantly increased | 79 |
doc id | 79 |
voluntary blood | 79 |
cord uid | 79 |
na seo | 79 |
host cells | 78 |
informed consent | 78 |
hemorrhagic fever | 78 |
high level | 78 |
donate blood | 77 |
infectious disease | 77 |
year old | 77 |
significantly lower | 77 |
body weight | 77 |
mg ml | 76 |
dna polymerase | 76 |
disease progression | 76 |
donated blood | 75 |
blood banking | 75 |
staphylococcus aureus | 74 |
last years | 74 |
buffy coat | 74 |
hemolytic transfusion | 74 |
monoclonal antibodies | 74 |
commercially available | 74 |
life cycle | 74 |
transfusion safety | 73 |
antibody identification | 73 |
genomic dna | 73 |
viral protein | 73 |
direct antiglobulin | 72 |
age group | 72 |
antigen expression | 71 |
pathogen reduction | 71 |
simplex virus | 71 |
rna viruses | 70 |
ebola virus | 70 |
cfu ml | 70 |
virus infections | 70 |
donor screening | 70 |
nucleic acids | 70 |
least one | 69 |
previous studies | 69 |
vertical transmission | 69 |
high prevalence | 69 |
yellow fever | 69 |
acute renal | 69 |
innate immune | 69 |
rhd gene | 68 |
window period | 68 |
world health | 68 |
hepatic encephalopathy | 68 |
cd cd | 68 |
human hepatitis | 68 |
envelope proteins | 68 |
adefovir dipivoxil | 67 |
adverse effects | 67 |
acute hepatitis | 67 |
iron deficiency | 67 |
log copies | 67 |
virus detection | 67 |
host cell | 67 |
care unit | 67 |
may occur | 66 |
two different | 66 |
false positive | 66 |
hbeag seroconversion | 66 |
nervous system | 66 |
sodium taurocholate | 65 |
hcc patients | 65 |
type ii | 65 |
serum samples | 65 |
envelope protein | 65 |
retrospective analysis | 65 |
hla antibodies | 64 |
reverse transcriptase | 64 |
transfusion transmitted | 64 |
liver tissues | 64 |
liver damage | 64 |
platelet products | 64 |
results showed | 63 |
study period | 63 |
critically ill | 63 |
per unit | 63 |
fever virus | 63 |
background aims | 63 |
united kingdom | 63 |
results show | 63 |
hsp inhibitors | 63 |
additive solution | 63 |
renal disease | 63 |
hematopoietic stem | 62 |
chronic infection | 62 |
liver fibrosis | 62 |
transfused patients | 62 |
respiratory syncytial | 62 |
liver cancer | 62 |
retrospective study | 62 |
human milk | 61 |
large number | 61 |
indirect antiglobulin | 61 |
platelet counts | 61 |
expressed breast | 61 |
growth factor | 61 |
hla class | 61 |
high frequency | 61 |
donor blood | 61 |
buffy coats | 61 |
rna polymerase | 61 |
rhce ce | 61 |
statistical analysis | 60 |
clinical trial | 60 |
hbeag negative | 60 |
case report | 60 |
general hospital | 60 |
one case | 60 |
results indicate | 60 |
hiv transmission | 60 |
ferritin levels | 60 |
within hours | 60 |
bact alert | 60 |
adaptive immune | 60 |
previously described | 60 |
results suggest | 59 |
ex vivo | 59 |
virus entry | 59 |
storage time | 59 |
cell disease | 59 |
cell transplantation | 59 |
human papillomavirus | 59 |
target cells | 59 |
blood screening | 59 |
abo blood | 59 |
see table | 58 |
male donors | 58 |
plasma units | 58 |
determine whether | 58 |
protein expression | 58 |
liver cells | 58 |
dendritic cells | 58 |
apheresis platelets | 58 |
infectious agents | 58 |
rna pol | 58 |
hbeag positive | 57 |
detection limit | 57 |
clinical significance | 57 |
cotransporting polypeptide | 57 |
nk cells | 57 |
taurocholate cotransporting | 57 |
barr virus | 57 |
significantly reduced | 57 |
million people | 57 |
blood type | 57 |
premature infants | 56 |
syncytial virus | 56 |
viral genome | 56 |
regional blood | 56 |
central nervous | 56 |
platelets stored | 56 |
lg ml | 56 |
hb level | 56 |
among patients | 56 |
column agglutination | 56 |
mouse model | 56 |
median age | 56 |
well tolerated | 56 |
specific cd | 56 |
blood sample | 56 |
blood management | 56 |
study showed | 56 |
negative blood | 55 |
hospital transfusion | 55 |
significant increase | 55 |
quality assurance | 55 |
transplant recipients | 55 |
test results | 55 |
may lead | 55 |
cirrhotic patients | 54 |
virus rna | 54 |
patients without | 54 |
repeat donors | 54 |
healthy controls | 54 |
serum alt | 54 |
reference laboratory | 54 |
may cause | 54 |
protein kinase | 54 |
rna virus | 54 |
scansystem tm | 54 |
health organization | 54 |
spectrum antiviral | 54 |
blood centre | 53 |
hemolytic anemia | 53 |
negative patients | 53 |
platelet transfusions | 53 |
systematic review | 53 |
infected individuals | 53 |
rare blood | 53 |
prospective study | 53 |
hbc positive | 53 |
significantly different | 53 |
treated cells | 53 |
gene therapy | 53 |
clinical symptoms | 53 |
antiviral agents | 53 |
japanese encephalitis | 53 |
abstract withdrawn | 53 |
positive dat | 52 |
abo rh | 52 |
virus dna | 52 |
expression level | 52 |
hdv infection | 52 |
transmitted infections | 52 |
quality management | 52 |
higher risk | 52 |
zoster virus | 52 |
allogeneic blood | 52 |
acute exacerbation | 52 |
monoclonal anti | 52 |
mortality rate | 52 |
zika virus | 52 |
positive donors | 51 |
long term | 51 |
core promoter | 51 |
hepatitis virus | 51 |
host immune | 51 |
trauma patients | 51 |
donor population | 51 |
dependent manner | 51 |
trima accel | 51 |
cell concentrates | 51 |
white blood | 51 |
patient blood | 50 |
among blood | 50 |
plt count | 50 |
hemolytic disease | 50 |
fetal dna | 50 |
target dna | 50 |
clinically relevant | 50 |
blood system | 50 |
hbv vaccine | 50 |
primer sets | 50 |
two patients | 50 |
ill patients | 50 |
packed red | 50 |
treated rbcs | 50 |
dna replication | 50 |
tested positive | 49 |
study group | 49 |
healthy donors | 49 |
chemokine receptor | 49 |
enveloped viruses | 49 |
pegylated interferon | 49 |
donor samples | 49 |
group antigens | 49 |
apheresis platelet | 49 |
cell units | 49 |
meld score | 49 |
storage period | 49 |
cell count | 48 |
years ago | 48 |
patient safety | 48 |
transgenic mice | 48 |
diabetes mellitus | 48 |
breast cancer | 48 |
coagulation factors | 48 |
class ii | 48 |
survival rate | 48 |
low hb | 48 |
cell transfusion | 48 |
blood establishments | 48 |
platelet units | 48 |
positive result | 48 |
plasma exchange | 48 |
liver tissue | 48 |
chronically infected | 48 |
total rna | 48 |
mononuclear cells | 48 |
regression analysis | 47 |
hbv viral | 47 |
significantly decreased | 47 |
units per | 47 |
human hepatocytes | 47 |
rbc transfusions | 47 |
post transfusion | 47 |
rhd negative | 47 |
ml kg | 47 |
birth weight | 47 |
hbv reactivation | 47 |
specific primers | 47 |
three times | 47 |
bile acid | 47 |
portal hypertension | 47 |
information system | 47 |
expression levels | 47 |
gel test | 47 |
pediatric patients | 46 |
standard deviation | 46 |
positive donations | 46 |
three patients | 46 |
rhd genotyping | 46 |
even though | 46 |
nucleoside analogues | 46 |
core antigen | 46 |
fully automated | 46 |
avian influenza | 46 |
disease severity | 46 |
center background | 46 |
clinical course | 46 |
positive cells | 46 |
year period | 46 |
significant antibodies | 46 |
alt levels | 46 |
patient care | 45 |
innate immunity | 45 |
one year | 45 |
reverse transcription | 45 |
results obtained | 45 |
platelet function | 45 |
nephrotic syndrome | 45 |
generation sequencing | 45 |
therapeutic plasma | 45 |
total bilirubin | 45 |
hcv replication | 45 |
cell death | 45 |
blood grouping | 44 |
body fluids | 44 |
platelet pools | 44 |
high levels | 44 |
residual risk | 44 |
platelet storage | 44 |
i ii | 44 |
platelet antigens | 44 |
virologic response | 44 |
terumo bct | 44 |
single donor | 44 |
wide range | 44 |
cell response | 44 |
positive rate | 44 |
lung injury | 44 |
adult patients | 44 |
related acute | 44 |
within days | 44 |
may result | 44 |
logistic regression | 44 |
oxidative stress | 44 |
real time | 44 |
encephalitis virus | 44 |
respiratory tract | 44 |
first step | 44 |
significant reduction | 43 |
child transmission | 43 |
days post | 43 |
iron depletion | 43 |
capsid protein | 43 |
clinical samples | 43 |
per patient | 43 |
syndrome coronavirus | 43 |
hbv genotype | 43 |
developing countries | 43 |
severe cases | 43 |
hbv related | 43 |
high sensitivity | 43 |
epithelial cells | 43 |
lupus erythematosus | 43 |
bacterial growth | 42 |
iron stores | 42 |
widely used | 42 |
hbv core | 42 |
time blood | 42 |
multivariate analysis | 42 |
patients infected | 42 |
like particles | 42 |
positive antibody | 42 |
immune complexes | 42 |
low level | 42 |
response rate | 42 |
reported cases | 42 |
acid testing | 42 |
hbv carriers | 42 |
positive control | 42 |
liver transplant | 42 |
cd cell | 42 |
decompensated cirrhosis | 42 |
analyzed using | 42 |
clinical manifestations | 41 |
donor recruitment | 41 |
low levels | 41 |
tested using | 41 |
dna viruses | 41 |
severe liver | 41 |
healthy individuals | 41 |
platelet yield | 41 |
clinical outcomes | 41 |
three months | 41 |
dna samples | 41 |
predictive value | 41 |
increased significantly | 41 |
inhibitory effect | 41 |
molecular biology | 41 |
fulminant hepatitis | 41 |
serious adverse | 41 |
rich plasma | 41 |
cell cycle | 41 |
platelet concentrate | 41 |
two years | 41 |
analysis showed | 41 |
clinical outcome | 41 |
east asia | 41 |
factors associated | 41 |
severe disease | 41 |
antibody tests | 41 |
cohort study | 41 |
circular dna | 41 |
clinical use | 40 |
cell antigens | 40 |
hong kong | 40 |
serum ferritin | 40 |
hb levels | 40 |
via breast | 40 |
blood plasma | 40 |
stranded rna | 40 |
quality system | 40 |
autoimmune diseases | 40 |
infection control | 40 |
single nucleotide | 40 |
hiv positive | 40 |
viral clearance | 40 |
health problem | 40 |
data suggest | 40 |
age groups | 40 |
also observed | 40 |
care workers | 40 |
endoplasmic reticulum | 40 |
routine use | 40 |
antibiotic therapy | 40 |
transfusion center | 40 |
pcr amplification | 40 |
alloimmune thrombocytopenia | 40 |
time points | 40 |
renal function | 40 |
studies showed | 40 |
related liver | 39 |
negative control | 39 |
transfusion related | 39 |
blood flow | 39 |
anti hpa | 39 |
hbv envelope | 39 |
stranded dna | 39 |
also found | 39 |
shock proteins | 39 |
alanine aminotransferase | 39 |
family members | 39 |
closely related | 39 |
binding site | 39 |
transfusion recipients | 39 |
iron supplementation | 39 |
transfusion practices | 39 |
neutralizing antibodies | 39 |
transmission via | 39 |
molecular weight | 39 |
systemic lupus | 38 |
platelet quality | 38 |
heparg cells | 38 |
hbs sirna | 38 |
nuclear import | 38 |
hospital blood | 38 |
ide analogues | 38 |
plasma membrane | 38 |
small number | 38 |
cancer cells | 38 |
host disease | 38 |
clinical characteristics | 38 |
cell proliferation | 38 |
western blotting | 38 |
current study | 38 |
virological response | 38 |
medical record | 38 |
viral entry | 38 |
laboratory tests | 38 |
effective treatment | 37 |
human cytomegalovirus | 37 |
th day | 37 |
direct contact | 37 |
bacterial screening | 37 |
compatible blood | 37 |
cobe spectra | 37 |
signaling pathway | 37 |
endemic areas | 37 |
recent studies | 37 |
viral particles | 37 |
neonatal alloimmune | 37 |
renal involvement | 37 |
gamma globulin | 37 |
shock syndrome | 37 |
animal models | 37 |
molecular methods | 37 |
high titer | 37 |
cell separator | 37 |
middle east | 37 |
measured using | 37 |
er stress | 37 |
screening tests | 37 |
human plasma | 37 |
severe thrombocytopenia | 37 |
flow cytometric | 37 |
month period | 37 |
transfusion associated | 37 |
treated patients | 37 |
cell types | 37 |
enzyme treated | 37 |
haemolytic disease | 37 |
protein levels | 36 |
information security | 36 |
three groups | 36 |
cd expression | 36 |
group systems | 36 |
immune globulin | 36 |
pcr assay | 36 |
bcp pc | 36 |
bacterial pneumonia | 36 |
dna virus | 36 |
allergic reactions | 36 |
hbsag levels | 36 |
donating blood | 36 |
patients showed | 36 |
screening test | 36 |
fatty liver | 36 |
urinary tract | 36 |
novel coronavirus | 36 |
hbv entry | 36 |
pregnant woman | 36 |
high incidence | 36 |
antibody detection | 36 |
apheresis procedures | 36 |
viral inactivation | 36 |
related complications | 36 |
viral loads | 36 |
tm platelet | 36 |
platelet concentration | 36 |
poor prognosis | 36 |
mass spectrometry | 36 |
management system | 36 |
higher prevalence | 36 |
hcv antibody | 36 |
toxic shock | 36 |
dna positive | 36 |
also performed | 36 |
patient received | 36 |
platelet kit | 36 |
phase ii | 35 |
much higher | 35 |
based assays | 35 |
serological testing | 35 |
bacterial detection | 35 |
natural history | 35 |
miu ml | 35 |
donor base | 35 |
adverse reaction | 35 |
free survival | 35 |
evaluated using | 35 |
positive blood | 35 |
lamp reaction | 35 |
american red | 35 |
extremely rare | 35 |
igg antibodies | 35 |
rhd positive | 35 |
adverse event | 35 |
high quality | 35 |
phase i | 35 |
breastfed infants | 35 |
three years | 35 |
clinical features | 35 |
clinical studies | 35 |
potential risk | 35 |
aclf patients | 35 |
high throughput | 34 |
drug users | 34 |
currently available | 34 |
shelf life | 34 |
mean hb | 34 |
significant changes | 34 |
specific primer | 34 |
controlled trial | 34 |
hbv cccdna | 34 |
major cause | 34 |
dna copies | 34 |
blot analysis | 34 |
survival rates | 34 |
samples tested | 34 |
cmv infection | 34 |
binding protein | 34 |
disease control | 34 |
using two | 34 |
plasma fractionation | 34 |
hepatitis delta | 34 |
well known | 34 |
new donors | 34 |
five patients | 34 |
confidence interval | 34 |
negative results | 34 |
mean platelet | 34 |
occult hbv | 34 |
randomized controlled | 34 |
vitro quality | 34 |
gold nanoparticles | 33 |
different blood | 33 |
insulin resistance | 33 |
alt normalization | 33 |
surface area | 33 |
previously reported | 33 |
plasma products | 33 |
regular blood | 33 |
positive chronic | 33 |
incubation period | 33 |
solid phase | 33 |
six months | 33 |
cancer patients | 33 |
laboratory testing | 33 |
several studies | 33 |
young children | 33 |
acute lung | 33 |
failure patients | 33 |
normal rhd | 33 |
many countries | 33 |
overall survival | 33 |
ml per | 33 |
nested pcr | 33 |
gene transcription | 33 |
gel electrophoresis | 33 |
reagent lots | 33 |
treatment group | 33 |
wild type | 33 |
scd patients | 33 |
cell embryos | 33 |
confirmed positive | 33 |
study shows | 33 |
european countries | 33 |
two cases | 33 |
case reports | 33 |
corrective actions | 33 |
four patients | 32 |
mg day | 32 |
hcv core | 32 |
host factors | 32 |
platelet refractoriness | 32 |
ethnic groups | 32 |
hbv infections | 32 |
chikungunya virus | 32 |
statistical significance | 32 |
virus core | 32 |
closed circular | 32 |
primary human | 32 |
growth factors | 32 |
auf die | 32 |
adaptive immunity | 32 |
liver inflammation | 32 |
liver cell | 32 |
hepatitis viruses | 32 |
lamivudine treatment | 32 |
highly sensitive | 32 |
cross blood | 32 |
hbv genotypes | 32 |
first months | 32 |
significant decrease | 32 |
hcv genotype | 32 |
high dose | 32 |
antiviral drug | 32 |
antiretroviral therapy | 32 |
within weeks | 32 |
escherichia coli | 32 |
hpa antibodies | 32 |
laboratory findings | 31 |
sanger sequencing | 31 |
tube method | 31 |
hcv infections | 31 |
months post | 31 |
control samples | 31 |
young people | 31 |
inflammatory cytokines | 31 |
mortality rates | 31 |
derived products | 31 |
past years | 31 |
sars coronavirus | 31 |
infection may | 31 |
broad spectrum | 31 |
log iu | 31 |
respiratory distress | 31 |
deferred donors | 31 |
acid amplification | 31 |
inhibit hbv | 31 |
hcv antibodies | 31 |
infected hepatocytes | 31 |
one unit | 31 |
neonatal intensive | 31 |
type hepatitis | 31 |
ml min | 31 |
vaccinia virus | 31 |
blood collected | 31 |
low risk | 31 |
stress proteins | 31 |
chronic hcv | 31 |
influenza vaccine | 31 |
patients suffering | 31 |
resistant staphylococcus | 31 |
selection criteria | 31 |
blood bags | 31 |
southern blot | 31 |
clinical data | 31 |
covalently closed | 31 |
stage liver | 31 |
dna load | 31 |
will also | 31 |
developed countries | 31 |
old female | 31 |
previous study | 31 |
endothelial cells | 31 |
units transfused | 30 |
early stage | 30 |
saharan africa | 30 |
immunosorbent assay | 30 |
patient samples | 30 |
reagent red | 30 |
patient population | 30 |
two types | 30 |
effector cells | 30 |
heterogeneous nuclear | 30 |
one study | 30 |
hcc cell | 30 |
bacterial infection | 30 |
mrna expression | 30 |
new york | 30 |
hbsag positive | 30 |
acute hbv | 30 |
hepatic fibrosis | 30 |
virus particles | 30 |
analytical sensitivity | 30 |
donor center | 30 |
agglutination technology | 30 |
study included | 30 |
well documented | 30 |
delta virus | 30 |
hepatic failure | 30 |
cell therapy | 30 |
structural proteins | 30 |
patient identification | 30 |
chronic viral | 30 |
genome sequences | 30 |
lateral flow | 30 |
cell activation | 30 |
igm antibodies | 30 |
transfusion protocol | 30 |
platelet components | 30 |
alt level | 30 |
enzyme immunoassay | 29 |
circulatory overload | 29 |
may affect | 29 |
common cause | 29 |
viral envelope | 29 |
also tested | 29 |
blood mononuclear | 29 |
transfusion vol | 29 |
emerging infectious | 29 |
nat screening | 29 |
analysis using | 29 |
electronic medical | 29 |
cervical cancer | 29 |
new blood | 29 |
human serum | 29 |
national health | 29 |
immunocompromised patients | 29 |
serologic tests | 29 |
rbc antigens | 29 |
tertiary care | 29 |
gold standard | 29 |
acute viral | 29 |
drug administration | 29 |
patients may | 29 |
pilot study | 29 |
highly conserved | 29 |
virus transmission | 29 |
analysis revealed | 29 |
hepatoma cell | 29 |
inventory management | 29 |
rna genome | 29 |
acute infection | 29 |
mhc class | 29 |
done using | 29 |
abo typing | 29 |
also showed | 29 |
regular donors | 29 |
dna synthesis | 29 |
cellular immune | 29 |
intravenous drug | 29 |
medical treatment | 29 |
ccr expression | 29 |
two samples | 29 |
medical staff | 29 |
storage lesion | 28 |
sybr green | 28 |
automated blood | 28 |
bleeding patients | 28 |
sectional study | 28 |
rare donor | 28 |
national institute | 28 |
human platelet | 28 |
respiratory failure | 28 |
operating procedures | 28 |
serum albumin | 28 |
heart disease | 28 |
several weeks | 28 |
control study | 28 |
czech republic | 28 |
also reported | 28 |
animal model | 28 |
per rbc | 28 |
human hepatoma | 28 |
manual tube | 28 |
observational study | 28 |
donor deferral | 28 |
decreased significantly | 28 |
rna positive | 28 |
influenza viruses | 28 |
transcription factors | 28 |
repeat blood | 28 |
study aimed | 28 |
wbc count | 28 |
serum levels | 28 |
may help | 28 |
significantly associated | 28 |
antiviral effect | 28 |
length hbv | 28 |
group antigen | 28 |
transfusion policy | 28 |
independent risk | 28 |
leading cause | 28 |
standard operating | 28 |
rhd typing | 28 |
small molecule | 28 |
retrospective review | 28 |
quantitative pcr | 28 |
per month | 28 |
antiviral activities | 28 |
blood derived | 28 |
bacterial meningitis | 28 |
pretransfusion testing | 28 |
linear regression | 28 |
transfusion chain | 28 |
high viral | 28 |
positive mothers | 28 |
time period | 27 |
physical examination | 27 |
least two | 27 |
maternal plasma | 27 |
plasma transfusion | 27 |
medical university | 27 |
transplant patients | 27 |
organ transplantation | 27 |
serologic testing | 27 |
hbsag loss | 27 |
large numbers | 27 |
screening assays | 27 |
results indicated | 27 |
may contribute | 27 |
necrosis factor | 27 |
relatively low | 27 |
six patients | 27 |
per day | 27 |
rhd exons | 27 |
mm tris | 27 |
wnv infection | 27 |
will help | 27 |
agarose gel | 27 |
south africa | 27 |
tumor necrosis | 27 |
induced liver | 27 |
high mortality | 27 |
associated nephropathy | 27 |
post irradiation | 27 |
general practitioners | 27 |
plasma volume | 27 |
tract infection | 27 |
molecular testing | 27 |
compatibility testing | 27 |
surgical procedures | 27 |
nucleoside analog | 27 |
seroconversion panels | 27 |
detection system | 27 |
patients developed | 27 |
fed infants | 27 |
intravenous immunoglobulin | 27 |
relatively high | 27 |
controlled trials | 27 |
ms ms | 27 |
treatment response | 27 |
plasma derivates | 27 |
cirrhosis patients | 27 |
infection among | 27 |
final concentration | 27 |
surgery patients | 27 |
five years | 27 |
applied biosystems | 27 |
abdominal pain | 27 |
like receptor | 27 |
inflammatory cells | 27 |
two major | 27 |
bile duct | 27 |
signaling pathways | 27 |
hemoglobin level | 27 |
cell antibodies | 26 |
single unit | 26 |
cell separators | 26 |
total blood | 26 |
hemoglobin levels | 26 |
exchange transfusion | 26 |
major challenge | 26 |
blood establishment | 26 |
usually associated | 26 |
data showed | 26 |
rna synthesis | 26 |
component therapy | 26 |
lyme disease | 26 |
viral resistance | 26 |
htlv i | 26 |
medical history | 26 |
platelet additive | 26 |
next generation | 26 |
routine testing | 26 |
irradiated blood | 26 |
occult hepatitis | 26 |
transfusion testing | 26 |
platelet aggregation | 26 |
laboratory data | 26 |
low frequency | 26 |
different types | 26 |
spectra optia | 26 |
leukemia virus | 26 |
mean value | 26 |
scoring system | 26 |
risk reduction | 26 |
virus genotype | 26 |
natural killer | 26 |
hbsag negative | 26 |
preliminary results | 26 |
congo hemorrhagic | 26 |
vasovagal reactions | 26 |
may provide | 26 |
high hbv | 26 |
denv infection | 26 |
cd deficiency | 26 |
three different | 26 |
hbv co | 26 |
table shows | 26 |
two days | 26 |
one month | 26 |
commonly used | 26 |
autoimmune hemolytic | 26 |
short period | 26 |
hepatoma cells | 26 |
university school | 26 |
study demonstrated | 26 |
transfected cells | 26 |
nuclear ribonucleoprotein | 26 |
hcv genotypes | 26 |
gene promoter | 26 |
internal control | 26 |
intercept blood | 26 |
negative controls | 26 |
borne viruses | 26 |
cells transfected | 25 |
cell survival | 25 |
sequence analysis | 25 |
authors declare | 25 |
showed significant | 25 |
mammalian cells | 25 |
negative result | 25 |
sexually transmitted | 25 |
last two | 25 |
weeks gestation | 25 |
white cell | 25 |
normal alt | 25 |
significant correlation | 25 |
liver dysfunction | 25 |
well established | 25 |
roche cobas | 25 |
hepatic cirrhosis | 25 |
immunosuppressive therapy | 25 |
old male | 25 |
notch signaling | 25 |
immune tolerance | 25 |
medical records | 25 |
molecules per | 25 |
russian federation | 25 |
capsid assembly | 25 |
virus load | 25 |
volume reduction | 25 |
allele frequencies | 25 |
samples obtained | 25 |
another study | 25 |
using different | 25 |
functional receptor | 25 |
diagnostic tests | 25 |
new automated | 25 |
haemolytic anaemia | 25 |
female donor | 25 |
gel cards | 25 |
fibrin glue | 25 |
specific immune | 25 |
hbv vaccination | 25 |
control groups | 25 |
apheresis donors | 25 |
platelet content | 25 |
surface expression | 25 |
via breastfeeding | 25 |
organ failure | 25 |
early diagnosis | 25 |
south america | 25 |
pulmonary edema | 25 |
copy number | 25 |
electron microscopy | 25 |
hbv gene | 25 |
chagas disease | 25 |
bacterial infections | 25 |
hospitalized patients | 25 |
cell leukemia | 25 |
iron overload | 25 |
cell free | 25 |
multiple myeloma | 25 |
also used | 25 |
open reading | 25 |
important roles | 25 |
recent study | 25 |
following transfusion | 25 |
sample size | 25 |
one sample | 25 |
group ab | 25 |
rbc unit | 24 |
clinical study | 24 |
automated system | 24 |
fi cation | 24 |
related hepatocellular | 24 |
complement activation | 24 |
hev rna | 24 |
cccdna synthesis | 24 |
nat testing | 24 |
antiviral agent | 24 |
allogenic blood | 24 |
quality improvement | 24 |
statistical difference | 24 |
respiratory viruses | 24 |
transmissible infections | 24 |
blood stem | 24 |
cell yield | 24 |
studies show | 24 |
molecular basis | 24 |
antibody positive | 24 |
thalassemic patients | 24 |
influenza vaccination | 24 |
limited number | 24 |
dna sequencing | 24 |
primary infection | 24 |
hbv infected | 24 |
may play | 24 |
hsp family | 24 |
detection methods | 24 |
rh typing | 24 |
normal range | 24 |
phylogenetic analysis | 24 |
risk assessment | 24 |
three days | 24 |
standard methods | 24 |
transfusion history | 24 |
donor safety | 24 |
target genes | 24 |
two weeks | 24 |
pall ebds | 24 |
times higher | 24 |
emergency department | 24 |
frequency antigens | 24 |
donor return | 24 |
samples showed | 24 |
low prevalence | 24 |
highly effective | 24 |
nucleoside analogue | 24 |
pooled platelet | 24 |
taken together | 24 |
specific antibody | 24 |
polyclonal anti | 24 |
transfusion centers | 24 |
mm edta | 24 |
vaccine candidate | 24 |
medical care | 24 |
culture medium | 24 |
donor platelets | 24 |
rna interference | 24 |
binding sites | 24 |
detected using | 24 |
two units | 24 |
time point | 24 |
ultrio assay | 24 |
transfusion process | 24 |
reactive samples | 24 |
antibody testing | 24 |
viral capsid | 24 |
dna sequence | 24 |
time consuming | 24 |
abo group | 24 |
national haemovigilance | 24 |
significant proportion | 23 |
duck hepatitis | 23 |
hcv infected | 23 |
coagulation factor | 23 |
received blood | 23 |
tumor suppressor | 23 |
increasing number | 23 |
splice site | 23 |
tested negative | 23 |
probably due | 23 |
herpes zoster | 23 |
randomly selected | 23 |
transfected huh | 23 |
high expression | 23 |
seasonal influenza | 23 |
laboratory parameters | 23 |
ethics committee | 23 |
mass index | 23 |
donor cells | 23 |
voluntary non | 23 |
persistent infection | 23 |
also occur | 23 |
renal dysfunction | 23 |
findings suggest | 23 |
male donor | 23 |
cost effective | 23 |
stored platelets | 23 |
delayed hemolytic | 23 |
hev infection | 23 |
deferral rates | 23 |
rna replication | 23 |
antibiotic treatment | 23 |
may serve | 23 |
bacterial culture | 23 |
turnaround time | 23 |
quality assessment | 23 |
soft tissue | 23 |
also determined | 23 |
hbv rna | 23 |
flow cytometer | 23 |
mayo clinic | 23 |
complete genome | 23 |
investigated whether | 23 |
venous blood | 23 |
peginterferon alfa | 23 |
income countries | 23 |
based transfusion | 23 |
rh phenotype | 23 |
organ transplant | 23 |
repeat testing | 23 |
autoimmune disease | 23 |
cold storage | 23 |
positive direct | 23 |
routine blood | 23 |
will provide | 23 |
signal transduction | 23 |
quantitative real | 23 |
mm na | 23 |
mainland china | 23 |
gram stain | 23 |
negative chronic | 23 |
life threatening | 23 |
among hiv | 23 |
pcr array | 23 |
day post | 23 |
take place | 23 |
viral antigens | 23 |
significantly correlated | 23 |
may reduce | 23 |
nucleotide polymorphisms | 23 |
transfusion strategy | 23 |
sexual partners | 23 |
investigate whether | 23 |
large volume | 23 |
cde cde | 23 |
antigen negative | 23 |
blood cultures | 23 |
viral hemorrhagic | 23 |
potent antiviral | 23 |
viral antigen | 23 |
viral gene | 23 |
among others | 23 |
pandemic influenza | 23 |
cytokine production | 23 |
lymphotropic virus | 23 |
false negative | 23 |
component preparation | 23 |
dna probes | 23 |
linked immunosorbent | 23 |
erythrocyte antibodies | 23 |
antibody responses | 23 |
arachidonic acid | 23 |
data collected | 23 |
year survival | 23 |
found positive | 23 |
rhd beadchip | 23 |
cell viability | 23 |
close contact | 23 |
antibodies directed | 23 |
compatible platelets | 23 |
months later | 23 |
ccr antagonists | 23 |
comparative study | 22 |
clinical relevance | 22 |
hbx sirna | 22 |
nafld patients | 22 |
blood conservation | 22 |
coronary artery | 22 |
serious complications | 22 |
polymerase activity | 22 |
determined using | 22 |
cellular immunity | 22 |
results demonstrate | 22 |
molecular techniques | 22 |
single dose | 22 |
related cirrhosis | 22 |
standard serological | 22 |
potential donors | 22 |
medical college | 22 |
antibody titer | 22 |
stimulating factor | 22 |
replacement donors | 22 |
fda approved | 22 |
twice daily | 22 |
important cause | 22 |
caucasian population | 22 |
nat assays | 22 |
replacement therapy | 22 |
decision making | 22 |
pol fidelity | 22 |
solid tumors | 22 |
data collection | 22 |
national guidelines | 22 |
hbeag loss | 22 |
future studies | 22 |
naturally occurring | 22 |
method using | 22 |
transfusion transmission | 22 |
hbv polymerase | 22 |
sample collection | 22 |
eight patients | 22 |
one week | 22 |
related hcc | 22 |
protective effect | 22 |
hiv hcv | 22 |
true positive | 22 |
entry inhibitors | 22 |
volunteer donors | 22 |
new technology | 22 |
derived platelets | 22 |
rhd weak | 22 |
cells per | 22 |
many patients | 22 |
internal medicine | 22 |
copy numbers | 22 |
rh blood | 22 |
donor deferrals | 22 |
greater risk | 22 |
viral pathogens | 22 |
gamma irradiation | 22 |
described previously | 22 |
three blood | 22 |
hb content | 22 |
platelet factor | 22 |
average number | 22 |
adverse transfusion | 22 |
primer set | 22 |
south african | 22 |
rna detection | 22 |
dna testing | 22 |
increased susceptibility | 22 |
working party | 22 |
blood centres | 22 |
molecular mechanisms | 22 |
transfusion laboratory | 22 |
different methods | 22 |
febrile non | 22 |
kinase inhibitors | 22 |
platelet activation | 22 |
free fetal | 22 |
hbv treatment | 22 |
umbilical cord | 22 |
protease inhibitors | 22 |
male patients | 22 |
natural products | 22 |
assessed using | 22 |
reactive results | 22 |
blood culture | 22 |
may require | 22 |
replicative homeostasis | 22 |
healthcare workers | 22 |
gestational age | 22 |
hemorrhagic fevers | 22 |
one single | 22 |
cell migration | 22 |
human liver | 22 |
patient outcomes | 22 |
transcription factor | 22 |
cell transfusions | 22 |
excessive bleeding | 22 |
chronic disease | 21 |
genotyping results | 21 |
pcr products | 21 |
healthy subjects | 21 |
colorimetric responses | 21 |
lassa fever | 21 |
one day | 21 |
hcc recurrence | 21 |
mucous membranes | 21 |
apheresis procedure | 21 |
human cells | 21 |
significantly improved | 21 |
curative resection | 21 |
nucleoside analogs | 21 |
viral suppression | 21 |
group i | 21 |
infected donors | 21 |
pregenomic rna | 21 |
seo treatment | 21 |
antimicrobial therapy | 21 |
chronic severe | 21 |
protease inhibitor | 21 |
dna amplification | 21 |
viral life | 21 |
european union | 21 |
data analysis | 21 |
related snps | 21 |
median time | 21 |
protein folding | 21 |
health sciences | 21 |
human cd | 21 |
mean number | 21 |
primed donor | 21 |
predonation hb | 21 |
positive reactions | 21 |
procleix ultrio | 21 |
therapeutic vaccination | 21 |
platelet loss | 21 |
key role | 21 |
molecular typing | 21 |
iron metabolism | 21 |
ntcp expression | 21 |
rbc products | 21 |
body mass | 21 |
urgent need | 21 |
hntcp cells | 21 |
direct detection | 21 |
age years | 21 |
low ferritin | 21 |
fluorescence intensity | 21 |
bacterial peritonitis | 21 |
two methods | 21 |
immune cells | 21 |
viral polymerase | 21 |
genetic variants | 21 |
clinical situations | 21 |
hfrg mice | 21 |
heart failure | 21 |
antigen presentation | 21 |
thrombocytopenic patients | 21 |
quantum dots | 21 |
antibody test | 21 |
ns ns | 21 |
restrictive transfusion | 21 |
rhd gamma | 21 |
combination treatment | 21 |
simultaneous detection | 21 |
give blood | 21 |
healthy blood | 21 |
molecular detection | 21 |
blood ordering | 21 |
hiv aids | 21 |
capsid proteins | 21 |
female patient | 21 |
surface protein | 21 |
vaccine development | 21 |
genome copies | 21 |
magnetic cards | 21 |
positive test | 21 |
different countries | 21 |
clinical setting | 21 |
geq ml | 21 |
may present | 21 |
culture system | 21 |
several years | 21 |
graft survival | 21 |
old individuals | 21 |
measles virus | 21 |
clinical efficacy | 21 |
inflammatory response | 21 |
viral diseases | 21 |
diabetic patients | 21 |
hospital background | 21 |
included patients | 21 |
stage renal | 21 |
hpv infection | 21 |
patienten mit | 21 |
vista tm | 21 |
external quality | 21 |
higher rates | 21 |
protein translation | 21 |
panel cells | 21 |
antibody titers | 21 |
new zealand | 20 |
basal core | 20 |
bite wounds | 20 |
smart phone | 20 |
east respiratory | 20 |
will allow | 20 |
platelet rich | 20 |
kidney transplantation | 20 |
hbv recurrence | 20 |
supply chain | 20 |
odds ratio | 20 |
hbv nat | 20 |
different clinical | 20 |
transfused units | 20 |
clinical settings | 20 |
treatment may | 20 |
vast majority | 20 |
closed system | 20 |
infected children | 20 |
elevated levels | 20 |
genome replication | 20 |
based assay | 20 |
iron status | 20 |
rh antigens | 20 |
prothrombin time | 20 |
cause severe | 20 |
rna levels | 20 |
typing results | 20 |
using commercial | 20 |
rubella virus | 20 |
infection occurs | 20 |
titer anti | 20 |
working group | 20 |
canadian blood | 20 |
resistance mutations | 20 |
environmental factors | 20 |
common causes | 20 |
potassium level | 20 |
multiple transfusions | 20 |
multiple sclerosis | 20 |
central blood | 20 |
hcv nat | 20 |
transfusion institute | 20 |
igg antibody | 20 |
one donor | 20 |
protein level | 20 |
naked eye | 20 |
fusion protein | 20 |
human igg | 20 |
kg day | 20 |
among different | 20 |
emergency blood | 20 |
portal vein | 20 |
spontaneous bacterial | 20 |
cell concentrate | 20 |
glucose tolerance | 20 |
dnase i | 20 |
testing using | 20 |
positive controls | 20 |
stored rbcs | 20 |
selectin expression | 20 |
using pcr | 20 |
rhd zygosity | 20 |
rhd variant | 20 |
shear stress | 20 |
plt transfusions | 20 |
several days | 20 |
clinical status | 20 |
long time | 20 |
adverse outcomes | 20 |
antibody specificity | 20 |
acid sequence | 20 |
screening assay | 20 |
dat positive | 20 |
massive necrosis | 20 |
per ml | 20 |
process control | 20 |
speci fi | 20 |
hbv group | 20 |
protein production | 20 |
first transfusion | 20 |
virus surface | 20 |
five days | 20 |
free dna | 20 |
remains unclear | 20 |
donor plasma | 20 |
practice guidelines | 20 |
leukocyte antibodies | 20 |
group ii | 20 |
human blood | 20 |
multiplex pcr | 20 |
leucocyte depleted | 20 |
high rates | 20 |
crystal structure | 20 |
transfusion committee | 20 |
nk cell | 20 |
serum creatinine | 20 |
patient groups | 20 |
hematopoietic cells | 20 |
surface antigens | 20 |
dtt treatment | 20 |
written informed | 20 |
virus genotypes | 20 |
isothermal amplification | 20 |
woodchuck hepatitis | 20 |
hybrid rhesus | 20 |
study aims | 20 |
mediated isothermal | 20 |
etv treatment | 20 |
genomic rna | 20 |
lactate dehydrogenase | 20 |
antibodies anti | 20 |
may develop | 20 |
high cost | 20 |
lung transplantation | 20 |
positive individuals | 20 |
return rates | 20 |
improve patient | 20 |
data indicate | 20 |
within min | 20 |
transfusion guidelines | 20 |
renal transplantation | 20 |
predictive factors | 20 |
ntcp cells | 20 |
zikv rna | 20 |
advisory committee | 20 |
performed according | 20 |
donor health | 20 |
copies per | 20 |
transfusion purpura | 20 |
chikv infection | 19 |
cellular factors | 19 |
genetic diversity | 19 |
respiratory disease | 19 |
storage conditions | 19 |
potent anti | 19 |
standard curve | 19 |
mononuclear cell | 19 |
pcr testing | 19 |
transfusion trigger | 19 |
intracranial hemorrhage | 19 |
virus reactivation | 19 |
potentially infectious | 19 |
million donations | 19 |
influenza infection | 19 |
nkt cells | 19 |
genetic material | 19 |
university medical | 19 |
upper respiratory | 19 |
patients underwent | 19 |
differentially expressed | 19 |
oral administration | 19 |
vault protein | 19 |
atpase activity | 19 |
intrauterine transfusions | 19 |
assay using | 19 |
patients requiring | 19 |
autoimmune haemolytic | 19 |
asian population | 19 |
repeated blood | 19 |
donors aged | 19 |
test group | 19 |
kidney transplant | 19 |
much lower | 19 |
health system | 19 |
host proteins | 19 |
also known | 19 |
manual method | 19 |
extremely low | 19 |
related adverse | 19 |
failure may | 19 |
radiofrequency ablation | 19 |
allele frequency | 19 |
assays using | 19 |
effective therapy | 19 |
ampli fi | 19 |
hna antibodies | 19 |
hiv replication | 19 |
brain edema | 19 |
random donor | 19 |
four years | 19 |
preoperative autologous | 19 |
cmv igg | 19 |
complete response | 19 |
samples collected | 19 |
may induce | 19 |
data management | 19 |
viral markers | 19 |
hla typing | 19 |
study population | 19 |
rheumatoid arthritis | 19 |
different stages | 19 |
connective tissue | 19 |
diagnostic criteria | 19 |
large surface | 19 |
fat diet | 19 |
evidence suggests | 19 |
treated platelets | 19 |
screening method | 19 |
family history | 19 |
bridging necrosis | 19 |
expression systems | 19 |
myocardial infarction | 19 |
treatment options | 19 |
tubular necrosis | 19 |
serological methods | 19 |
days later | 19 |
west africa | 19 |
mainly due | 19 |
local blood | 19 |
platelet antibodies | 19 |
negative women | 19 |
lactate production | 19 |
platelet collection | 19 |
cell salvage | 19 |
treponema pallidum | 19 |
sample volume | 19 |
cobas amplicor | 19 |
effective use | 19 |
nine patients | 19 |
spotted fever | 19 |
memory cd | 19 |
transmitted diseases | 19 |
surgical patients | 19 |
negative samples | 19 |
total dna | 19 |
different time | 19 |
vitro studies | 19 |
transfusion hepatitis | 19 |
effector functions | 19 |
disease virus | 19 |
therapeutic effect | 19 |
nitric oxide | 19 |
well plates | 19 |
marrow transplantation | 19 |
relative risk | 19 |
also significantly | 19 |
theraflex mb | 19 |
drug development | 19 |
high rate | 19 |
positive correlation | 19 |
hematology analyzer | 19 |
days storage | 19 |
platelet inventory | 19 |
irregular antibodies | 19 |
interferon alpha | 19 |
chicken pox | 19 |
transmitted via | 19 |
evidence indicates | 19 |
vox sang | 19 |
vesicular stomatitis | 19 |
pcr assays | 19 |
less common | 19 |
septic shock | 19 |
virus disease | 19 |
transfusion support | 19 |
amotosalen uva | 19 |
patient survival | 19 |
many studies | 19 |
donor retention | 19 |
directive ec | 19 |
haemolytic transfusion | 19 |
interstitial nephritis | 19 |
lamivudine resistance | 19 |
cells may | 19 |
old man | 19 |
global health | 19 |
human infection | 19 |
evidence based | 19 |
wt wt | 19 |
type diabetes | 19 |
control measures | 19 |
terminal domain | 19 |
homologous blood | 19 |
data show | 19 |
rh system | 19 |
based blood | 19 |
cell entry | 19 |
photochemical treatment | 19 |
consecutive patients | 18 |
inventory levels | 18 |
hla antibody | 18 |
virus ns | 18 |
major vault | 18 |
severe complications | 18 |
rhd variants | 18 |
low birth | 18 |
one rbc | 18 |
blood systems | 18 |
early detection | 18 |
poc tests | 18 |
cell epitopes | 18 |
hiv ag | 18 |
hcv patients | 18 |
haemovigilance systems | 18 |
outcome review | 18 |
cell damage | 18 |
cell cultures | 18 |
wide spectrum | 18 |
clinically important | 18 |
cell apoptosis | 18 |
volunteer blood | 18 |
intcp cells | 18 |
infectious mononucleosis | 18 |
strongly recommended | 18 |
membranous nephropathy | 18 |
routinely used | 18 |
wb units | 18 |
using flow | 18 |
virus strain | 18 |
graphene oxide | 18 |
donor platelet | 18 |
factor ix | 18 |
local population | 18 |
protective immunity | 18 |
antigen positive | 18 |
facs analysis | 18 |
remunerated blood | 18 |
female patients | 18 |
north america | 18 |
del phenotype | 18 |
quality controls | 18 |
lymph nodes | 18 |
acquired pneumonia | 18 |
primary hepatocytes | 18 |
mds patients | 18 |
exclusive breastfeeding | 18 |
virus hepatitis | 18 |
two donors | 18 |
process time | 18 |
donors will | 18 |
inh titre | 18 |
lst system | 18 |
tupaia hepatocytes | 18 |
antibody response | 18 |
main reason | 18 |
patients died | 18 |
one hour | 18 |
tube testing | 18 |
cell panel | 18 |
gambro bct | 18 |
promoter region | 18 |
primer pairs | 18 |
similar results | 18 |
operative infections | 18 |
diagnostic accuracy | 18 |
viral safety | 18 |
architect i | 18 |
autovue innova | 18 |
infants born | 18 |
hbv transcription | 18 |
free haemoglobin | 18 |
published data | 18 |
hospital based | 18 |
large envelope | 18 |
monolisa hcv | 18 |
higher levels | 18 |
health authorities | 18 |
data obtained | 18 |
detection systems | 18 |
cold antibodies | 18 |
mm nacl | 18 |
ebv infection | 18 |
cells expressing | 18 |
plus ribavirin | 18 |
igg molecules | 18 |
patients will | 18 |
pc mutation | 18 |
hepatic decompensation | 18 |
ag ab | 18 |
pres peptide | 18 |
dna sequences | 18 |
hbc negative | 18 |
therapeutic strategies | 18 |
inhibitory effects | 18 |
gastrointestinal bleeding | 18 |
positive impact | 18 |
complex formation | 18 |
graft versus | 18 |
highly variable | 18 |
next step | 18 |
dna concentration | 18 |
platelet recovery | 18 |
hospital stay | 18 |
chronic carriers | 18 |
rhd exon | 18 |
blood count | 18 |
play important | 18 |
task force | 18 |
surface ntcp | 18 |
studies suggest | 18 |
alert system | 18 |
tumor cells | 18 |
children younger | 18 |
collected using | 18 |
many years | 18 |
success rate | 18 |
also included | 18 |
culture media | 18 |
treated red | 18 |
results suggested | 18 |
blood bag | 18 |
well plate | 18 |
tumor recurrence | 18 |
th centile | 18 |
rbc collection | 18 |
small heat | 18 |
disease patients | 18 |
cell antibody | 18 |
presenting cells | 18 |
case group | 18 |
gradient centrifugation | 18 |
serum bilirubin | 18 |
virus genome | 18 |
significant impact | 18 |
subviral particles | 18 |
resistant hbv | 18 |
old woman | 18 |
tissue damage | 18 |
years period | 18 |
routine screening | 18 |
significant effect | 18 |
viral rnas | 18 |
blood shortages | 18 |
individual donation | 18 |
waiting list | 18 |
patients experienced | 18 |
infected mothers | 18 |
clinical evidence | 18 |
positive reaction | 18 |
shock response | 18 |
variant viral | 18 |
methylene blue | 18 |
background aim | 18 |
general hospitals | 18 |
partial ds | 18 |
hcv positive | 18 |
negative bacteria | 18 |
hsp inhibitor | 18 |
coding sequence | 18 |
cells ml | 18 |
final product | 18 |
health services | 18 |
drug use | 18 |
optimised scansystem | 18 |
dna detection | 17 |
prevalence antigen | 17 |
ae ml | 17 |
human origin | 17 |
protein sequences | 17 |
transmission occurs | 17 |
reading frame | 17 |
every year | 17 |
hcv coinfection | 17 |
renal impairment | 17 |
progressive disease | 17 |
viral genomes | 17 |
fungal infections | 17 |
tube methods | 17 |
total hbv | 17 |
cell patients | 17 |
rejuvenation solution | 17 |
varicella zoster | 17 |
clinical diagnostics | 17 |
protein synthesis | 17 |
infectious agent | 17 |
membrane proteins | 17 |
negative effects | 17 |
surface proteins | 17 |
rna testing | 17 |
hb values | 17 |
chinese population | 17 |
activated protein | 17 |
mrna levels | 17 |
mrna level | 17 |
rocky mountain | 17 |
genetic variations | 17 |
discrepant results | 17 |
internal controls | 17 |
transfusion protocols | 17 |
volume processed | 17 |
abbott laboratories | 17 |
disease associated | 17 |
genetic variant | 17 |
low rate | 17 |
th cells | 17 |
hospital admission | 17 |
genetic distance | 17 |
interferon alfa | 17 |
th week | 17 |
large amounts | 17 |
cyclophilin inhibitors | 17 |
aplastic anemia | 17 |
allogeneic hsct | 17 |
i sr | 17 |
igm positive | 17 |
clinical development | 17 |
staff training | 17 |
within months | 17 |
swine fever | 17 |
cells via | 17 |
low titer | 17 |
hbsag prevalence | 17 |
transfusion strategies | 17 |
abbott prism | 17 |
ferritin level | 17 |
industrialized countries | 17 |
standard deviations | 17 |
square test | 17 |
donations per | 17 |
base apparatus | 17 |
hyaluronic acid | 17 |
hbs ag | 17 |
woodchuck model | 17 |
molecular chaperone | 17 |
sciences authority | 17 |
plasma replacement | 17 |
differential diagnosis | 17 |
time rt | 17 |
icu stay | 17 |
hbv drugs | 17 |
prevent hbv | 17 |
live attenuated | 17 |
clinical diagnosis | 17 |
sars virus | 17 |
genome equivalents | 17 |
will require | 17 |
mountain spotted | 17 |
term newborns | 17 |
higher incidence | 17 |
female blood | 17 |
inflammatory responses | 17 |
energy transfer | 17 |
voluntary donors | 17 |
oxygen delivery | 17 |
may become | 17 |
infection via | 17 |
platelet specific | 17 |
high fat | 17 |
human parvovirus | 17 |
remained stable | 17 |
safety profile | 17 |
seroconversion rate | 17 |
human ntcp | 17 |
antibody screens | 17 |
spinal cord | 17 |
large scale | 17 |
research institute | 17 |
antigen typing | 17 |
storage duration | 17 |
every hours | 17 |
organ transplants | 17 |
coronary heart | 17 |
serological tests | 17 |
entry inhibitor | 17 |
hnrnp i | 17 |
acute bronchitis | 17 |
sialic acid | 17 |
respiratory illness | 17 |
pf antibody | 17 |
immune evasion | 17 |
immediate spin | 17 |
ccr gene | 17 |
clinical signs | 17 |
study also | 17 |
cardiac diseases | 17 |
less frequent | 17 |
receptor binding | 17 |
blood utilization | 17 |
emerging viruses | 17 |
factors affecting | 17 |
patients aged | 17 |
sample preparation | 17 |
tumor cell | 17 |
cytomegalovirus infection | 17 |
species transmission | 17 |
blood processing | 17 |
pc mutations | 17 |
cases reported | 17 |
low viral | 17 |
focal segmental | 17 |
serum level | 17 |
health status | 17 |
risks associated | 17 |
regression model | 17 |
study performed | 17 |
chronically transfused | 17 |
negative red | 17 |
healthy control | 17 |
rhd immunization | 17 |
using anti | 17 |
virus large | 17 |
among first | 17 |
inhibits hepatitis | 17 |
stomatitis virus | 17 |
liver samples | 17 |
clinical impact | 17 |
three cases | 17 |
transfusion sample | 17 |
gel card | 17 |
oral iron | 17 |
weeks later | 17 |
molecular analysis | 17 |
alkaline phosphatase | 17 |
related mortality | 17 |
flaviviridae family | 17 |
methods used | 17 |
dat negative | 17 |
transfected hepg | 17 |
immune complex | 17 |
neutralizing antibody | 17 |
pancreatic cancer | 17 |
multiorgan failure | 17 |
low molecular | 17 |
science foundation | 17 |
considered significant | 17 |
clinical conditions | 17 |
negative donors | 17 |
apache ii | 17 |
venezuelan equine | 17 |
thawed plasma | 17 |
anemic patients | 17 |
mean volume | 17 |
transient expression | 17 |
blood inventory | 16 |
transfusion requirements | 16 |
high affinity | 16 |
molecular mechanism | 16 |
many cases | 16 |
least weeks | 16 |
components issued | 16 |
tested samples | 16 |
rbc exchange | 16 |
aiha patients | 16 |
random donors | 16 |
nat yield | 16 |
ten years | 16 |
rotavirus infection | 16 |
african americans | 16 |
rsv infection | 16 |
kell antigens | 16 |
study revealed | 16 |
significant role | 16 |
within years | 16 |
cd monoclonal | 16 |
cell apheresis | 16 |
often found | 16 |
reduction technology | 16 |
specific dna | 16 |
transfusion activities | 16 |
treg cells | 16 |
gpib expression | 16 |
myeloid leukemia | 16 |
per week | 16 |
contamination risk | 16 |
varicella vaccine | 16 |
testing results | 16 |
intracranial pressure | 16 |
flow chart | 16 |
hcv prevalence | 16 |
usually occurs | 16 |
antiviral efficacy | 16 |
higher frequency | 16 |
special attention | 16 |
without agitation | 16 |
also cause | 16 |
haemovigilance data | 16 |
will lead | 16 |
useful tool | 16 |
ic values | 16 |
infected blood | 16 |
fulminant hepatic | 16 |
randomized trial | 16 |
slightly lower | 16 |
labile blood | 16 |
platelet apheresis | 16 |
dna viral | 16 |
vaccination programs | 16 |
predicted phenotype | 16 |
affected patients | 16 |
suspected cases | 16 |
positive effect | 16 |
false positives | 16 |
first line | 16 |
patients transfused | 16 |
time quantitative | 16 |
sensitive detection | 16 |
human hepatocellular | 16 |
natural science | 16 |
abo incompatibility | 16 |
hubei province | 16 |
gpiib iiia | 16 |
liver enzymes | 16 |
lactic acid | 16 |
product utilization | 16 |
multiply transfused | 16 |
positive women | 16 |
fresh platelets | 16 |
blood borne | 16 |
different anti | 16 |
hand hygiene | 16 |
million inhabitants | 16 |
matrix protein | 16 |
reverse grouping | 16 |
hereditary hemochromatosis | 16 |
erythrocyte concentrates | 16 |
preliminary data | 16 |
endothelial cell | 16 |
mean time | 16 |
three types | 16 |
last months | 16 |
fetal rhd | 16 |
rhd alleles | 16 |
system antibodies | 16 |
gene editing | 16 |
ttv dna | 16 |
regulatory requirements | 16 |
treatment failure | 16 |
gene deletion | 16 |
associated hcc | 16 |
rbcs stored | 16 |
autologous rbcs | 16 |
also shown | 16 |
gene sequences | 16 |
medical doctors | 16 |
positively correlated | 16 |
electrical impedance | 16 |
first year | 16 |
nucleotide sequences | 16 |
hcv transmission | 16 |
severe transfusion | 16 |
malignant diseases | 16 |
nuclear localization | 16 |
post donation | 16 |
failure caused | 16 |
serological markers | 16 |
showed high | 16 |
bovine serum | 16 |
blood types | 16 |
male patient | 16 |
information regarding | 16 |
like receptors | 16 |
bleeding disorders | 16 |
transferrin saturation | 16 |
taurocholate co | 16 |
hbv antigen | 16 |
blood tests | 16 |
information systems | 16 |
rare red | 16 |
renal transplant | 16 |
residual leukocytes | 16 |
viral particle | 16 |
rbc alloimmunization | 16 |
donor unit | 16 |
prism hbsag | 16 |
standard precautions | 16 |
fresenius kabi | 16 |
hypotonic shock | 16 |
hiv rna | 16 |
ns protein | 16 |
lysis buffer | 16 |
conditioning regimen | 16 |
decompensated liver | 16 |
jakob disease | 16 |
hcv ag | 16 |
statistical significant | 16 |
pathogen reduced | 16 |
human coronavirus | 16 |
reactive oxygen | 16 |
acute phase | 16 |
preoperative anemia | 16 |
first report | 16 |
hepatic stellate | 16 |
rbc alloantibodies | 16 |
acid residues | 16 |
infective endocarditis | 16 |
cccdna formation | 16 |
adverse effect | 16 |
processing set | 16 |
study conducted | 16 |
healthy volunteers | 16 |
autologous donors | 16 |
major histocompatibility | 16 |
high specificity | 16 |
also important | 16 |
readily available | 16 |
dependent rna | 16 |
low blood | 16 |
coding region | 16 |
inhibits hbv | 16 |
four different | 16 |
observation period | 16 |
rna chaperones | 16 |
normal saline | 16 |
hcv ns | 16 |
treatment option | 16 |
prospective cohort | 16 |
timely manner | 16 |
maternal alloantibody | 16 |
donor program | 16 |
specific ctl | 16 |
rbc membrane | 16 |
overall mortality | 16 |
also evaluated | 16 |
term follow | 16 |
beta thalassemia | 16 |
cell membrane | 16 |
small interfering | 16 |
inflammatory process | 16 |
rhd diiia | 16 |
clinical response | 16 |
patients compared | 16 |
vital signs | 16 |
bei patienten | 16 |
strand dna | 16 |
cross match | 16 |
also increased | 16 |
waiting time | 16 |
recent advances | 16 |
allogeneic donors | 16 |
serum igg | 16 |
thermo fisher | 16 |
every days | 16 |
quality blood | 16 |
i will | 16 |
compatible units | 16 |
clotting factors | 16 |
blood testing | 16 |
genetic variation | 16 |
irregular antibody | 16 |
often associated | 16 |
plasmid containing | 16 |
descriptive study | 16 |
ab plasma | 16 |
way anova | 16 |
receive blood | 16 |
primary endpoint | 16 |
cell growth | 16 |
log reduction | 16 |
curative treatment | 16 |
hepatorenal syndrome | 15 |
institutional review | 15 |
two main | 15 |
specific anti | 15 |
many different | 15 |
term effects | 15 |
delta antigen | 15 |
initial treatment | 15 |
seven days | 15 |
sirna expression | 15 |
ferritin testing | 15 |
deep sequencing | 15 |
studies comparing | 15 |
hiv testing | 15 |
refractory patients | 15 |
family donors | 15 |
different ethnic | 15 |
liver stiffness | 15 |
prostate cancer | 15 |
control bags | 15 |
living space | 15 |
standard tube | 15 |
viral pneumonia | 15 |
temporary deferral | 15 |
ub ml | 15 |
expressing cells | 15 |
whole genome | 15 |
higher mortality | 15 |
first blood | 15 |
cell counter | 15 |
abo grouping | 15 |
oxygen species | 15 |
genetic variability | 15 |
cell counting | 15 |
sustained virological | 15 |
considered statistically | 15 |
membrane fusion | 15 |
significant relationship | 15 |
clinical sensitivity | 15 |